Encapsulation of Vincristine in Liposomes Reduces its Toxicity and Improves its Anti-Tumor Efficacy

References

• Gregoriadis G., Nerunjun E. D. Treatment of tumor bearing mice with liposome-entrapped actinomycin D prolongs their survival. Res. Commun. Chem. Pathol. Pharmacol. 1975; 10: 351
   PubMedGoogle Scholar
• Forssen E. A., Tokes Z. A. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc. Natl. Acad. Sci. USA 1981; 78: 1873
   PubMed Web of Science ®Google Scholar
• Rahman A., More N., Schein P. S. Doxorubicin-induced chronic cardiotoxicity and its protection by liposomal administration. Cancer Res. 1982; 42: 1817
   PubMed Web of Science ®Google Scholar
• Gabizon A., Dagan A., Goren D., Barenholz Y., Fuks Z. Liposomes as in vivo carriers of Adriamycin: reduced cardiac uptake and preserved anti-tumor activity in mice. Cancer Res. 1982; 42: 4734
   PubMed Web of Science ®Google Scholar
• Herman E. H., Rahman A., Ferrans V. J., Vicks J. A., Schein P. S. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res. 1983; 43: 5427
   PubMed Web of Science ®Google Scholar
• Gabizon A., Goren D., Fuks Z., Barenholz Y., Dagan A., Meshorer A. Enhancement of Adriamycin delivery to liver metastatic cells with increased tumoricidal effect using liposomes as drug carriers. Cancer Res. 1983; 43: 4730
   PubMed Web of Science ®Google Scholar
• Mayhew E., Rustum Y. M. The use of liposomes as carriers of therapeutic agents. Prog. Clin. Biol. Res. 1985; 172B: 301
   PubMedGoogle Scholar
• Hunt C. A., Rustum Y. M., Mayhew E., Papahadjopoulos D. Retention of cytosine arabinoside in mouse lung following intravenous administration in liposomes of different size. Drug Metab. Dispos. 1979; 7: 124
   PubMed Web of Science ®Google Scholar
• Kobayashi T., Kataoka T., Tsukagoshi S., Sakurai Y. Enhancement of antitumor activity of 1-beta-D-arabinofuranosylcytosine by encapsulation in liposomes. Int. J. Cancer 1977; 20: 581
   PubMed Web of Science ®Google Scholar
• Fichtner I., Reszka R., Elbe B., Arndt D. Therapeutic evaluation of liposome-encapsulated daunoblastin in murine tumor models. Neoplasma (Bratisl.) 1981; 28: 141
   PubMed Web of Science ®Google Scholar
• Forssen E. A. Chemotherapy with anthracycline-liposomes. “Liposomes as Drug Carriers”, G. Gregoriadis. John Wiley and Sons, New York 1988; 355
   Google Scholar
• Woo S. Y., Dilliplane P., Rahman A., Sinks L. F. Liposomal methotrexate in the treatment of murine L1210 leukemia. Cancer Drug Delivery 1983; 1: 59
   PubMedGoogle Scholar
• Mayer L. D., Bally M. B., Loughrey H, Masin D., Cullis P. R. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 1990; 50: 575
   PubMed Web of Science ®Google Scholar
• Carter S. K., Livingston R. B. Plant products in cancer chemotherapy. Cancer Treat. Rep. 1976; 60: 1141
   PubMedGoogle Scholar
• Sieber S. M., Mead J. A. R., Adamson R. H. Pharmacology of anti-tumor agents from higher plants. Cancer Treat. Rep. 1976; 60: 1127
   PubMedGoogle Scholar
• Owellen R. J., Hartke C. A., Dickerson R. M., Hains F. O. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res. 1976; 36: 1499
   PubMed Web of Science ®Google Scholar
• Owellen R. J., Owens A. J., Jr., Donigian D. W. The binding of vincristine, vinblastine, and colchicine to tubulin. Biochem. Biophys. Res. Commun. 1972; 47: 685
   PubMed Web of Science ®Google Scholar
• Bally M. B., Nayar R., Masin D., Hope M. J., Cullis P. R., Mayer L. D. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim. Biophys. Acta 1990; 1023: 133
   PubMed Web of Science ®Google Scholar
• Mayer L. D., Bally M. B., Cullis P. R., Wilson S. L., Emerman J. T. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and anti-tumor efficacy in the SCI 15 murine mammary tumor. Cancer Lett. 1990; 53: 183
   PubMed Web of Science ®Google Scholar
• Jackson D. V., Jr., Bender R. A. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res. 1979; 39: 4346
   PubMed Web of Science ®Google Scholar
• Chappel J. B., Crofts A. R. “Regulation of metabolic processes in mitochondria”, J. M. Tage, S. Papa, E. Quaglieriello, E. C. Slater. Elsevier, Amsterdam 1966; 293
   Google Scholar
• Crofts A. R. Amine uncoupling of energy transfer in chloroplasts. I. Relation to ammonium ion uptake. J. of Biol. Chem. 1967; 242: 3352
   PubMed Web of Science ®Google Scholar
• Mayer L. D., Bally M. B., Hope M. J., Cullis P. R. Techniques for encapsulating bioactive agents into liposomes. Chem. Phys. Lipids 1986; 40: 333
   PubMed Web of Science ®Google Scholar
• Addanki S., Cahill F. D., Sotos J. F. Determination of intramitochondrial pH and intramitochondrial-extramitochondrial pH gradient of isolated heart mitochondria by the use of 5,5-dimethyl-2,4-oxazolidinedione. I. Changes during respiration and adenosine triphosphate-dependent transport of Ca++, Mg++, and Zn++. J. Biol. Chem. 1968; 243: 2337
   PubMed Web of Science ®Google Scholar
• Rottenberg H. The measurement of membrane potential and pH in cells, organelles, and vesicles. Methods in Enzymology 1979; 55: 547
   PubMedGoogle Scholar
• Mayer L. D., Nayar R, Thies R. L., Boman N. L., Cullis P. R., Bally M. B. Identification of vesicle properties that enhance the anti-tumor activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother. Pharmacol. 1993; 33: 17
   PubMed Web of Science ®Google Scholar
• Boman N. L., Mayer L. D., Cullis P. R. Optimization of the retention properties of vincristine in liposomal systems. Biochim. Biophys. Acta 1993; 1152: 253
   PubMed Web of Science ®Google Scholar
• Boman N. L., Masin D., Mayer L. D., Cullis P. R., Bally M. B. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res. 1994; 54: 2830
   PubMed Web of Science ®Google Scholar
• Webb M. S., Harasym T. O., Masin D., Bally M. B., Mayer L. D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumor models. Brit. J. Cancer 1995, In Press
   Web of Science ®Google Scholar
• Kanter P. M., Klaich G. M., Bullard G. A., King J. M., Bally M. B., Mayer L. D. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anti-Cancer Drugs 1994; 5: 579
   PubMed Web of Science ®Google Scholar
• Boman N. L., Tron V. A., Bally M. B., Cullis P. R. Vincristine induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother. Pharmacol. 1995, In Press
   Web of Science ®Google Scholar
• Mayer L. D., Masin D., Nayar R., Boman N. L., Bally M. B. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumors. Brit. J. Cancer 1995; 71: 482
   PubMed Web of Science ®Google Scholar
• Bally M. B., Masin D, Nayar R., Cullis P. R., Mayer L. D. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother. Pharmacol. 1994; 34: 137
   PubMed Web of Science ®Google Scholar